Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Inflammation > JAK1 > Flashcards

JAK1 Flashcards

1
Q

What phase of development is PFE JAK1 (Atopic Dermatitis)?

A

Ph2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What/when is next milestone for PFE JAK1 (Atopic Dermatitis)?

A

POC, 2018

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Atopic Dermatitis symptoms

A

-dry/scaly itchy patches appear on skin (often on face)-small fluid-filled blisters may form

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Atopic Dermatitis prevalence

A

up to 20% of children, up to 3% of adults~17% of population

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Atopic Dermatitis burden of disease (healthcare costs)

A

Xxx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Atopic Dermatitis standard of care

A

topical steroids and calcineurin inhibitors, but many patients don’t receive adequate relief

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Which indications Pfizer Pursuing?

A

Atopic Dermatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Atopic Dermatitis Projected Peak Sales

A

Xxxx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Atopic Dermatitis PF-‘0841 - advantages / disadvantages

A

advantage: the only JAK1 inhibitor being developed for atopic dermatitis disadvantage: >24 months behind pipeline leaders dupilumab, for moderate to severe patients, and crisaborole, for mild to moderate patients, (both in Ph3), low competitive timing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What competitors in Atopic Dermatitis? (All MOA)

A

In-class (all target JAK1):

Ph2:

  1. Filgotinib of Galapagos (RA)
  2. ABT-494 of Abbott (CD & RA)
  3. INCB-39110 of Incyte (cancer)
  4. INCB-52793 of Incyte (cancer)

Ph1:

  1. INCB-39110 of Incyte (cancer)

In-landscape:

Ph3:

  1. Dupilumab of Regeneron/Sanofi (IL4R)
  2. Crisaborole of Anacor (PDE4)

Ph2:

  1. Lebrikizumab of Roche (IL13)
  2. Tralokinumab of AZ (IL13)
  3. AQX-1125 of Aquinox (SHIP)
  4. CIM331 of Chugai (IL31)
  5. DS107G of Dignity Sci (unknown)
  6. HL009 of HanAll (NO synthase)
  7. OC459 of Atopix (CRTH2)
  8. OPA-15406 of Otsuka (PDE4)
  9. Otezla of Celgene (PDE4)
  10. QAW039 of Novartis (CRTH2)
  11. WBI-1001 of GSK (CCK2)
  12. Photocil of Applied Bio (unknown)
  13. Q301 of Quirent (unknown)
  14. SB011 of Sterna (GATA3)
  15. Ligelizumab of Tanox (IgE)
  16. DRM-02 of Dermira (ILK)

Ph1: 6 competitors in Ph1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Atopic Dermatitis Prevalence

A

31.6 million with eczema, and at least 17.8 million with moderate to severe eczema or atopic dermatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Atopic Dermatitis Standard of Care

A

topical therapy: antihistamines, corticosteroids, etc.

phototherapy/systemic agents: phototherapy, immunomodulatory/antimocrobial/antihistamine systemic agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Peak Sales Projection

A

XXX

How well did you know this?
1
Not at all
2
3
4
5
Perfectly

Inflammation (7 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions